For the quarter ending 2025-09-30, BLND had $17,704K increase in cash & cash equivalents over the period. -$5,762K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income (loss) from continuing operations | 12,410 | -10,256 |
| Stock-based compensation | 7,766 | 13,610 |
| Depreciation and amortization | 1,041 | 1,047 |
| Amortization of deferred contract costs | 429 | 746 |
| Amortization of debt discount and issuance costs | 0 | 0 |
| Amortization of operating lease right-of-use assets | 151 | 199 |
| Accelerated amortization of right-of-use asset in connection with lease abandonment | 0 | - |
| Gain on investment in equity securities | 16,580 | 0 |
| Loss on extinguishment of debt | 0 | 0 |
| Gain on sale of insurance business | 0 | - |
| Other | 39 | 316 |
| Trade and other receivables | -2,709 | 364 |
| Prepaid expenses and other assets, current and non-current | 3,447 | 1,262 |
| Deferred contract costs, non-current | -263 | 531 |
| Accounts payable | -429 | -419 |
| Deferred revenue | -7,421 | 12,734 |
| Accrued compensation | 1,650 | -684 |
| Operating lease liabilities | -712 | -1,921 |
| Other liabilities, current and non-current | -524 | 2,210 |
| Net cash provided by (used in) operating activities - continuing operations | -2,733 | 14,793 |
| Net cash used in operating activities - discontinued operations | -757 | -771 |
| Net cash provided by (used in) operating activities | -3,490 | 14,022 |
| Purchases of marketable securities | 6,741 | 23,749 |
| Sale of available-for-sale securities | 19,968 | 859 |
| Maturities of marketable securities | 16,500 | 27,727 |
| Additions to property, equipment and internal-use software development costs | 2,272 | 8,320 |
| Other | 0 | - |
| Proceeds from sale of insurance business | 0 | - |
| Investment in non-marketable equity securities | 0 | 4,000 |
| Net cash provided by investing activities - continuing operations | 27,455 | -7,483 |
| Net cash used in investing activities - discontinued operations | -62 | -120 |
| Net cash provided by investing activities | 27,393 | -7,603 |
| Proceeds from exercises of stock options, including early exercises, net of repurchases | 712 | 793 |
| Taxes paid related to net share settlement of equity awards | 1,886 | 5,502 |
| Share repurchases | 5,025 | 4,118 |
| Repayment of long-term debt | 0 | 0 |
| Net proceeds from the issuance of the series a redeemable convertible preferred stock and the haveli warrant | 0 | 0 |
| Payment for issuance costs related to the series a redeemable convertible preferred stock and the haveli warrant | 0 | 0 |
| Net cash used in financing activities - continuing operations | -6,199 | -8,827 |
| Effect of exchange rates on cash, cash equivalents, and restricted cash | 0 | 0 |
| Net increase in cash, cash equivalents, and restricted cash | 17,704 | -2,408 |
| Cash and cash equivalents at beginning of period | 49,537 | - |
| Cash and cash equivalents at end of period | 64,833 | - |
Blend Labs, Inc. (BLND)
Blend Labs, Inc. (BLND)